FTM
KALV

First Turn Management’s KalVista Pharmaceuticals KALV Stock Holding History

First Turn Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-214,138
Closed -$2.42M – 35
2025
Q2 		$2.42M Buy
+214,138
New +$2.62M 0.45% 34
2024
Q4 		– Sell
-355,000
Closed -$4.11M – 39
2024
Q3 		$4.11M Sell
355,000
-704,540
-66% -$8.86M 0.65% 38
2024
Q2 		$12.5M Sell
1,059,540
-119,880
-10% -$1.4M 2.03% 28
2024
Q1 		$14M Buy
+1,179,420
New +$15.7M 2.09% 27

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

First Turn Management's KALV Position: Q3 2025 in Review

First Turn Management sold out of KalVista Pharmaceuticals (KALV) in Q3 2025, closing a stake of 214,138 shares — an estimated $2.42M sold.

First Turn Management first reported a position in KALV in Q1 2024 and held it in 4 quarters. The position peaked at $14M in Q1 2024. 145 funds tracked by Wall St. Rank hold KALV as of Q3 2025.

  • First Turn Management reported no remaining KalVista Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • First Turn Management sold 214,138 KalVista Pharmaceuticals shares in Q3 2025, an estimated $2.42M.
  • First Turn Management first reported a position in KalVista Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • First Turn Management's KalVista Pharmaceuticals position peaked at $14M in Q1 2024.
  • 145 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2025.

Based on First Turn Management's 13F filing for Q3 2025, filed 14 Nov 2025.